ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Trading Up 3.3 %
Shares of NASDAQ:ACAD traded up $0.52 during trading hours on Friday, reaching $16.26. The stock had a trading volume of 48,170 shares, compared to its average volume of 1,860,590. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -12.39 and a beta of 0.71. The business's fifty day moving average price is $15.73 and its two-hundred day moving average price is $20.06. ACADIA Pharmaceuticals has a 52-week low of $12.24 and a 52-week high of $28.06.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The company had revenue of $134.56 million during the quarter, compared to the consensus estimate of $130.06 million. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative return on equity of 41.18%. ACADIA Pharmaceuticals's revenue for the quarter was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.27) earnings per share. Equities research analysts anticipate that ACADIA Pharmaceuticals will post -1.36 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on ACAD shares. SVB Leerink reduced their target price on ACADIA Pharmaceuticals from $27.00 to $21.00 and set an "outperform" rating on the stock in a report on Tuesday. Cowen reduced their target price on ACADIA Pharmaceuticals from $32.00 to $21.00 and set an "outperform" rating on the stock in a report on Monday. Royal Bank of Canada dropped their price target on ACADIA Pharmaceuticals from $26.00 to $21.00 and set an "outperform" rating for the company in a research report on Tuesday. Jefferies Financial Group lowered ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and dropped their price target for the stock from $25.00 to $10.00 in a research report on Tuesday, June 21st. Finally, The Goldman Sachs Group dropped their price target on ACADIA Pharmaceuticals from $20.00 to $15.00 and set a "neutral" rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $22.72.